Company intelligence / Profile preview

HighField Biopharmaceuticals

Hangzhou, Zhejiang, Chinahighfieldbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

HighField Biopharmaceuticals has demonstrated promising safety and efficacy signals in early clinical studies. Its lead program HF1K16 showed good tolerability and immune modulation in solid tumor patients with preliminary efficacy signals, especially in glioma cohorts. The company’s mRNA-based HFG1 program has shown significant weight loss and HbA1c reduction in diabetic monkeys. IND clearance was granted in China to begin a Phase I trial of the novel T cell engager HF50 targeting solid tumors[3][5][9].

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Liposome-based therapeutics (immunoliposomes)Lipid nanoparticles (LNP) for gene therapy/mRNA deliveryAntibody-drug conjugates (ADC)mRNA therapeutics
Industry: Biotech

Drug pipeline

10 assets

HF1K16

9 more assets in the full pipeline.

Beyond the preview

Go deeper on HighField Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HighField Biopharmaceuticals.